Compare · BNTX vs FENC
BNTX vs FENC
Side-by-side comparison of BioNTech SE (BNTX) and Fennec Pharmaceuticals Inc. (FENC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and FENC operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $21.65B, about 72.1x FENC ($300.5M).
- Over the past year, BNTX is down 18.3% and FENC is up 6.0% - FENC leads by 24.3 points.
- FENC has been more active in the news (16 items in the past 4 weeks vs 8 for BNTX).
- BNTX has more recent analyst coverage (25 ratings vs 5 for FENC).
- Company
- BioNTech SE
- Fennec Pharmaceuticals Inc.
- Price
- $86.17-0.37%
- $8.71-0.85%
- Market cap
- $21.65B
- $300.5M
- 1M return
- -7.68%
- +22.61%
- 1Y return
- -18.29%
- +5.96%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 8
- 16
- Recent ratings
- 25
- 5
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- The Multi-Billion-Dollar Search for Better Glioblastoma Treatments
- SEC Form 6-K filed by BioNTech SE
- Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
- BioNTech upgraded by UBS with a new price target
- Bernstein initiated coverage on BioNTech with a new price target
- SEC Form 6-K filed by BioNTech SE
- BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
- SEC Form 6-K filed by BioNTech SE
- BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
Latest FENC
- SEC Form 4 filed by Director Brughera Marco Maria
- SEC Form 4 filed by Director Cook Jodi A
- SEC Form 4 filed by Director Islam Khalid
- SEC Form 4 filed by Director Rallis Chris A
- Fennec Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Fennec Announces Results of Annual Meeting
- Director Raykov Rosty was granted 2,778 shares, exercised 15,597 shares at a strike of $2.45 and sold $93,766 worth of shares (9,747 units at $9.62) as part of a pre-agreed trading plan, increasing direct ownership by 7% to 130,079 units (SEC Form 4)
- Chief Strategy Officer Cioffi Christiana Marie was granted 156 shares, increasing direct ownership by 0.65% to 24,176 units (SEC Form 4)
- Chief Executive Officer Hackman Jeffrey S. was granted 1,159 shares, increasing direct ownership by 2% to 62,825 units (SEC Form 4)
- CHIEF FINANCIAL OFFICER Andrade Robert was granted 1,703 shares, increasing direct ownership by 0.59% to 289,269 units (SEC Form 4)